Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature

Xin Li; Shijiang Xing; Qiumei Dong

doi:10.18632/oncotarget.17406

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature

Xin Li, Shijiang Xing and Qiumei Dong _

PDF | HTML | How to cite

Oncotarget. 2017; 8:55760-55765. https://doi.org/10.18632/oncotarget.17406

Metrics: PDF 1137 views | HTML 2242 views | ?

Abstract

Xin Li1, Shijiang Xing1 and Qiumei Dong2

1Department of Medical Oncology, Xiaolan People's Hospital Affiliated to Southern Medical University, Zhongshan, China

2Department of Medical Oncology, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

Correspondence to:

Qiumei Dong, email: [email protected]

Keywords: Down syndrome, non-small-cell lung cancer, EGFR mutation, trisomy 21, EGFR-TKIs resistance

Received: February 07, 2017 Accepted: April 03, 2017 Published: April 25, 2017

ABSTRACT

Background: Solid tumors have a markedly decreased incidence in individuals with Down syndrome (DS), including lung cancers.

Methods: The clinical presentation of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) in DS was reported and literature on the subject reviewed.

Results: In individuals with DS, the risk of lung cancer appears markedly lower. EGFR mutation and EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance also exist in DS with lung cancer.

Conclusions: Clinicians should consider EGFR mutation and EGFR-TKIs resistance in lung cancer patients with DS.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17406

Publication Alerts

Case Reports:

Epidermal growth factor receptor-mutant lung cancer in Down syndrome: a case presentation and review of the literature

Abstract